Drug intelligence / Profile preview

miR-21 mimic

Development stage
Preclinical
Modality
MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Topical, Subcutaneous
01

Overview

miR-21 mimic is a research-stage synthetic, double-stranded RNA oligonucleotide designed to replicate the biological activity of endogenous microRNA-21 (miR-21). As a microRNA replacement therapy, it functions by binding to the 3' untranslated regions (UTRs) of target mRNAs, leading to translational repression or mRNA degradation. In preclinical metabolic research, miR-21 mimics have demonstrated the ability to prevent high-fat diet-induced weight gain by promoting white adipose tissue browning and thermogenesis. Additionally, it has been explored for cutaneous wound healing by regulating PDCD4 and matrix metalloproteinases. While miR-21 is often overexpressed in cancers (acting as an oncomiR), its therapeutic mimicry is primarily investigated in regenerative medicine and metabolic health across various academic institutions.

Brand names
MISSIONmirVanamiRIDIAN
Other names
microRNA-21 mimicmicroRNA21 mimicmicroRNA 21 mimichsa-miR-21 mimichsa-miR21 mimichsa-miR 21 mimicmiR-21-5p mimicmiR21-5p mimicmiR 21-5p mimic
02

Targets

PDCD4 (Programmed cell death protein 4)

Beyond the preview

Go deeper on miR-21 mimic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on miR-21 mimic.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call